Drug intelligence / Profile preview

HMM-920

Development stage: Preclinical
Lead developer: Help Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Oral

Overview

HMM-920 is an allogeneic, off-the-shelf cell therapy candidate developed by Help Therapeutics using an induced pluripotent stem cell (iPSC) platform. It is specifically designed for the treatment of motor system diseases. As a regenerative medicine product, HMM-920 aims to restore function by replacing or regenerating damaged cells within the motor system, rather than through the modulation of specific molecular targets. The therapy is currently in the concept validation or preclinical stage of development.

Beyond the preview

Go deeper on HMM-920.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMM-920.

Explore the full profile